Theravance SVP has 6,258 shares withheld for taxes

Theravance Biopharma, Inc. (TBPH) reported that officer Aine Miller, SVP, DEV & HEAD OF IRE OFFICE, had 6,258 Ordinary Shares withheld on 2026-08-20 to satisfy tax obligations from the vesting of previously granted restricted stock units.

Rhea-AI Filing Summary

Theravance Biopharma, Inc. (TBPH) reported that officer Aine Miller, SVP, DEV & HEAD OF IRE OFFICE, had 6,258 Ordinary Shares withheld on 2026-08-20 to satisfy tax obligations from the vesting of previously granted restricted stock units. The shares were withheld by the issuer, not sold in an open market transaction, leaving Miller with 189,826 Ordinary Shares held directly after the transaction.

Insider Trade Summary

Tax Withholding: 6,258 shares

Tax Withholding 1 txn

Insider Miller Aine

Role SVP, DEV & HEAD OF IRE OFFICE

Type	Security	Shares	Price	Value
Tax Withholding	Ordinary Shares F1	6,258	$16.95	$106K

Holdings After Transaction: Ordinary Shares — 189,826 shares (Direct)

Footnotes (1)

1. F1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

Key Figures

Shares withheld: 6,258 Ordinary Shares Withholding price per share: $16.95 per share Shares owned after transaction: 189,826 Ordinary Shares +1 more

4 metrics

Shares withheld 6,258 Ordinary Shares Withheld on 2026-08-20 to satisfy tax obligations from RSU vesting

Withholding price per share $16.95 per share Value used for the 6,258 shares withheld for tax obligations

Shares owned after transaction 189,826 Ordinary Shares Direct ownership of Aine Miller following the 2026-08-20 transaction

Code F shares 6,258 shares Reported as payment of tax liability by delivering or withholding securities

Key Terms

restricted stock units, open market transaction, Payment of tax liability by delivering or withholding securities

3 terms

restricted stock units financial

"tax obligations arising out of the vesting of previously granted restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

open market transaction financial

"The share withholding transaction was with the issuer and did not involve an open market transaction"

An open market transaction is a buy or sell of publicly traded securities executed on an exchange or other public trading venue where many buyers and sellers can participate. It matters to investors because these trades change the visible supply and demand for a stock—like shoppers moving prices in a busy marketplace—affecting share price, liquidity (how easily you can trade), and sometimes the balance of ownership.

Payment of tax liability by delivering or withholding securities financial

"transaction_code_description: Payment of tax liability by delivering or withholding securities"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TBPH officer Aine Miller report on this Form 4?

The Form 4 reports that 6,258 Ordinary Shares of Theravance Biopharma, Inc. (TBPH) were withheld from officer Aine Miller on 2026-08-20 to cover tax obligations arising from the vesting of previously granted restricted stock units.

Was the TBPH Form 4 transaction an open market sale of shares?

No. The footnote states the share withholding transaction was with the issuer and did not involve an open market transaction. Shares were withheld solely to satisfy tax obligations from vesting restricted stock units.

At what price per share were TBPH shares withheld in Aine Miller’s transaction?

The shares were withheld at a price of $16.95 per Ordinary Share, used to determine the value of the 6,258 shares withheld to satisfy tax obligations related to the vesting of restricted stock units.

How many TBPH shares does Aine Miller hold after the reported tax withholding?

After the tax-withholding transaction, Aine Miller directly holds 189,826 Ordinary Shares of Theravance Biopharma, Inc. The Form 4 reports this figure as the total shares owned following the transaction.

What was the purpose of the TBPH share disposition reported by Aine Miller?

The disposition of 6,258 Ordinary Shares was to satisfy tax obligations resulting from the vesting of previously granted restricted stock units. The issuer withheld the shares for this purpose rather than Miller selling them in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 06:05 PM EDT Accepted by SEC EDGAR 08/24/2026 - 06:04 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller Aine

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, DEV & HEAD OF IRE OFFICE

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/20/2026		F		6,258(1)	D	$16.95	189,826	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

	/s/ Brett A Grimaud, Attorney-in-Fact	08/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)